BioCentury
ARTICLE | Company News

Dyax other research news

October 7, 1996 7:00 AM UTC

Dyax received a $100,000 Phase I SBIR grant from the NIH for preclinical development of an agent to image inflammation in several diseases. The agent is based on a small protein that targets neutrophi...